For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Abion Inc.

Calculating rank

USPTO Granted Patents = 20

% Expired Patents = 15.0

CIPO Patents = 3

EPO Patents = 6

Forward Citations = 1

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Jun Young Choi (10 out of 39 patents)

Young Kee Shin (10 out of 24 patents)

Na Young Kim (4 out of 8 patents)

4. Young-Deug Kim (3 out of 5 patents)

5. Sung Youl Hong (3 out of 3 patents)

6. Ji Hye Lee (2 out of 99 patents)

7. Kyoung Song (2 out of 5 patents)

8. Yun Su Lee (2 out of 2 patents)

9. En Sel Oh (2 out of 5 patents)

10. Yong Ho In (2 out of 3 patents)

11. Mi Jeong Kwon (2 out of 3 patents)

12. Sang Seok Koh (2 out of 3 patents)

13. Yoon La Choi (2 out of 2 patents)

14. Tae Eun Kim (2 out of 3 patents)

15. Kyung-eui Park (2 out of 5 patents)

20 patents: Sort by Forward Citations

1. 12582707 - IN-VITRO TRANSCRIPT MRNA AND PHARMACEUTICAL COMPOSITION COMPRISING SAME (2026-03-24),

2. 12377132 - Method for treating or sensitizing interferon beta resistant cancer comprising cFLIP siRNA (2025-08-05),

3. 12371437 - Method of preparing camsylate salts of triazolopyrazine derivatives (2025-07-29),

4. 12275740 - Method of inhibiting kinase by camsylate salts of triazolopyrazine derivatives (2025-04-14),

5. 12173074 - Anti-c-Met agonist antibody and use thereof (2024-12-24),

6. 12098198 - Antibody binding specifically to ECL-2 of claudin 3, fragment thereof, and use thereof (2024-09-24),

7. 11987582 - Maleate salts of triazolopyrazine derivatives, compositions, methods of use, and processes of manufacturing the same (2024-05-21),

8. 11759500 - PEGylated interferon-beta variant (2023-09-19),

9. 11464832 - Composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA (2022-10-11),

10. 11286296 - Anti-human ninjurin-1 (NINJ-1) antibodies and methods for detecting human NINJ-1 (2022-03-29),

11. 11207411 - Stabilized preparation of interferon beta variant (2021-12-28),

12. 11111536 - Method for determining cross contamination of mouse genes for human cells in a patient-derived xenograft cells (2021-09-07),

13. 11107552 - Data processing, analysis method of gene expression data to identify endogenous reference genes (2021-08-31),

14. 10576158 - Immune conjugate having dendron conjugated to antibody and use thereof (2020-03-03),

15. 10538529 - Polymorphic forms of triazolopyrazine derivatives and method of preparing the same (2020-01-21),

Company Overview

Abion Inc. is a biotechnology company based in Seoul, South Korea, specializing in the development of innovative therapeutic solutions. The organization focuses on research in areas such as biopharmaceuticals and regenerative medicine, leveraging advanced technologies to address unmet medical needs. Abion is committed to enhancing healthcare outcomes through its cutting-edge research and development efforts, aiming to deliver effective treatments that improve patient quality of life.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

20 Patents

#230 in Seoul

#635 in South Korea

#31,295 in the World

Seoul, South Korea

Abion Inc.

Forward Citations = 1

45 inventors:

Jun Young Choi (10 out of 39 patents)

Young Kee Shin (10 out of 24 patents)

Na Young Kim (4 out of 8 patents)

4. Young-Deug Kim (3 out of 5 patents)

5. Sung Youl Hong (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abion Inc.. Retrieved from https://idiyas.com/company/abion

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…